Transfer of marker genes into hemopoietic progenitor cells

Malcolm Brenner, Helen Heslop, Donna Rill, Congfen Li, Colton Smith, Robert Krance, Cliona Rooney, Malcolm Brenner

Research output: Contribution to journalArticle

2 Scopus citations

Abstract

Ex vivo gene marking of normal and malignant hemopoietic cells allows the cells to be subsequently tracked in vivo. Marking has shown that even when marrow is in remission, it may contain malignant cells that contribute to relapse. These studies have also shown that it is possible to obtain long-term gene expression in human long-lived hemopoietic progenitor cells and T lymphocytes in vivo. Current marker studies use two distinguishable vectors to track two distinctively treated cell populations in a single individual. This modification greatly increases the power of the technique. It is now possible to study the effects of purging on residual malignant cells in marrow, to determine the action of growth-promoting agents (such as cytokines and stroma) on short- and long-term repopulation by transduced marrow, and to discover which phenotypic subsets of hemopoietic progenitor cells have long-term repopulating potential. The information gained will be invaluable for improving therapeutic gene transfer protocols in which marrow-derived cells are the targets.

Original languageEnglish (US)
Pages (from-to)193-200
Number of pages8
JournalCytokines and Molecular Therapy
Volume2
Issue number3
StatePublished - Nov 15 1996

Keywords

  • Gene transfer
  • Hemopoietic cells
  • Marker genes
  • Marrow
  • Neomycin phosphotransferase
  • Stem cell transplantation
  • T lymphocytes

ASJC Scopus subject areas

  • Pharmacology
  • Immunology and Allergy

Fingerprint Dive into the research topics of 'Transfer of marker genes into hemopoietic progenitor cells'. Together they form a unique fingerprint.

Cite this